Moreover, in the sex, weight, race, individual cancer stage, tumour grade, nodal metastasis, and TP53 mutation status subgroup analyses, the expression of LYRM4 mRNA was also significantly higher in LIHC patients (Fig. 2). This evidence concerns the gene TP53 and neoplasm.